Paving roads for new drugs in oncology

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 2, 2009, Pages 137-145

  Zaenker, Kurt S ^a   Entschladen, Frank ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Biomarkers; Drug regulatory affairs; Kinase inhibitor; Monoclonal antibody; Personalized therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DASATINIB; DEHYDRODIDEMNIN B; DIGITOXIN; ERLOTINIB; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GLUCOSE TRANSPORTER ANTIBODY; IBRITUMOMAB TIUXETAN; IMATINIB; LAPATINIB; MELPHALAN; NILOTINIB; PACLITAXEL; PANITUMUMAB; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TORICEL; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL STUDY; DISEASE MARKER; DRUG DEVELOPMENT; DRUG INDICATION; DRUG POTENTIATION; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; GLYCOLYSIS; HIGH THROUGHPUT SCREENING; HUMAN; LEGAL ASPECT; LYMPHATIC LEUKEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; REVIEW; CLINICAL TRIAL; DRUG APPROVAL; DRUG INDUSTRY; EUROPE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; NEOPLASM; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; DRUG DISCOVERY; DRUG INDUSTRY; EUROPE; GOVERNMENT AGENCIES; GUIDELINES AS TOPIC; HUMANS; NEOPLASMS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 68949132968     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209788452795     Document Type: Review

References (73)

1. Reaves ND. A model of effective health policy: The 1983 orphan drug act. J Health Soc Policy 2003; 17: 61-71.
2. Committee for Orphan Medicinal Products. Commission Regulation (EC) No 847/2000 of 27 April 2000. Off J Eur Commun 2000; L103: 5-8.
3. Wall ME. Camptothecin and taxol: Discovery to clinic. Med Res Rev 1998; 18: 299-314.
4. Caers J, Menu E, De Raeve H, et al. Antitumour and antiangiogenic effects of Aplidin in the 5TMM syngeneic models of multiple myeloma. Br J Cancer 2008; 98: 1966-1974.
5. Mitsiades CS, Ocio EM, Pandiella A, et al. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res 2008; 68: 5216-5225.
6. Siddiq A, Dembitsky V. Acetylenic anticancer agents. Anticancer Agents Med Chem 2008; 8: 132-170.
7. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
8. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008; 13: 472-482.
9. Cangiano J, Centeno BA, Garrett CR, et al. Signal transduction proteins in tumors from puerto rican and caucasian gastric adenocarcinoma patients: Expression differences with potential for specific targeted therapies. Dig Dis Sci 2008; 53: 2090-2100.
10. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008; 27(47): 6120-6130.
11. Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology 2008; 52: 108-118.
12. Goldman JM, Melo JV. BCR-ABL in chronic myelogenous leukemia - How does it work? Acta Haematol 2008; 119: 212-217.
13. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994; 15: 450-454.
14. Rowan WC, Hale G, Tite JP, Brett SJ. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995; 7: 69-77.
15. Domagala A, Kurpisz M. CD52 antigen: A review. Med Sci Monit 2001; 7: 325-331.
16. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008; 8: 156-171.
17. Traxler P, Allegrini PR, Brandt R, et al. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004; 64: 4931-4941.
18. Zhang W, Gordon M, Lenz HJ. Novel approaches to treatment of advanced colorectal cancer with anti-EGFR monoclonal antibodies. Ann Med 2006; 38: 545-551.
19. Entschladen F, Palm D, Drell TL, Lang K, Zaenker KS. Connecting a tumor to the environment. Curr Pharm Des 2007; 13: 3440-3444.
20. Hawley RC, Kiessling LL, Schreiber SL. Model of the interactions of calichemicin gamma 1 with a DNA fragment from pBR322. Proc Natl Acad Sci USA 1989; 86: 1105-1109.
21. Walker S, Landovitz R, Ding WD, Ellestad GA, Kahne D. Cleavage behavior of calicheamicin gamma 1 and calicheamicin T. Proc Natl Acad Sci USA 1992; 89: 4608-4612.
22. Grobe K, Powell LD. Role of protein kinase C in the phosphorylation of CD33 (Siglec-3) and its effect on lectin activity. Blood 2002; 99: 3188-3196.
23. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-1934.
24. Ma WW, Jimeno A. Temsirolimus. Drugs Today (Barc) 2007; 43: 659-669.
25. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin Cancer Res 2008; 14: 1286-1290.
26. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharmacol Res 2007; 55: 477-486.
27. Masur K, Lang K, Niggemann B, Zanker KS, Entschladen F. High PKC alpha and low E-cadherin expression contribute to high migratory activity of colon carcinoma cells. Mol Biol Cell 2001; 12: 1973-1982.
28. Kumar A, Petri ET, Halmos B, Boggon TJ. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol 2008; 26: 1742-1751.
29. Arora A, Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther 2005; 315: 971-979.
30. Jones D, Thomas D, Yin CC, et al. Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors. Cancer 2008; 113(5): 985-994.
31. Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006; 66: 11851-11858.
32. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer:Ttherapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
33. Omura S, Iwai Y, Hirano A, et al. A new alkaloid AM-2282 of Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot (Tokyo) 1977; 30: 275-282.
34. Vieth M, Higgs RE, Robertson DH, Shapiro M, Gragg EA, Hemmerle H. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Biochim Biophys Acta 2004; 1697: 243-257.
35. Wilkinson SE, Parker PJ, Nixon JS. Isoenzyme specificity of bisindolylmaleimides, selective inhibitors of protein kinase C. Biochem J 1993; 294 (Pt 2): 335-337.
36. Wilson DP, Sutherland C, Borman MA, Deng JT, Macdonald JA, Walsh MP. Integrin-linked kinase is responsible for Ca2+-independent myosin diphosphorylation and contraction of vascular smooth muscle. Biochem J 2005; 392: 641-648.
37. Niiro N, Ikebe M. Zipper-interacting protein kinase induces Ca(2+)-free smooth muscle contraction via myosin light chain phosphorylation. J Biol Chem 2001; 276: 29567-29574.
38. McFate T, Mohyeldin A, Lu H, et al. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J Biol Chem 2008; 283(33): 22700-22708.
39. Haux J. Digitoxin is a potential anticancer agent for several types of cancer. Med Hypotheses 1999; 53: 543-548.
40. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633-4646.
41. Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007; 257: 244-251.
42. Schultes RE. Amazonian ethnobotany in the search for new drugs. CIBA Foundation Symposium - Ethnobotany and the search for new drugs. In: Chadwick DJ, Marsh J, Eds. John Wiley & Sons: Chichester 1994, pp. 106-115.
43. Balick MJ. Ethnobotany and the identification of therapeutic agents from rainforest. CIBA Foundation Symposium - Bioactive compounds from plants. In: Chadwick DJ, Marsh J, Eds. John Wiley & Sons: Chichester 1990, pp. 22-39.
44. Mans DR, da Rocha AB, Schwartsmann G. Anti-cancer drug discovery and development in Brazil: Targeted plant collection as a rational strategy to acquire candidate anti-cancer compounds. Oncologist 2000; 5: 185-98.
45. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005; 78: 431-441.
46. Schwartsmann G, Da Rocha AB, Mattei J, Lopes R. Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 2003; 12: 1367-1383.
47. Rawat DS, Joshi MC, Joshi P, Atheaya H. Marine peptides and related compounds in clinical trial. Anticancer Agents Med Chem 2006; 6: 33-40.
48. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): A randomised trial. Lancet 2007; 370: 1209-1218.
49. Algazi M, Plu-Bureau G, Flahault A, Dondon MG, Le MG. Could treatments with beta-blockers be associated with a reduction in cancer risk? Rev Epidemiol Sante Publique 2004; 52: 53-65.
50. Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 2004; 15: 535-541.
51. Fryzek JP, Poulsen AH, Lipworth L, et al. A cohort study of antihypertensive medication use and breast cancer among Danish women. Breast Cancer Res Treat 2006; 97: 231-236.
52. Drell TL, Joseph J, Lang K, Niggemann B, Zaenker KS, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80: 63-70.
53. Lang K, Drell TL, Lindecke A, et al. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112: 231-238.
54. Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by beta-blockers. Cancer Res 2001; 61: 2866-2869.
55. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006; 118: 2744-2749.
56. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Neurotransmitters and chemokines regulate tumor cell migration: Potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005; 11: 403-411.
57. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: Navigation by neurotransmitters. Lancet Oncol 2004; 5: 254-258.
58. Balakin KV, Ivanenkov YA, Tkachenko SE, Kiselyov AS, Ivachtchenko AV. Regulators of chemokine receptor activity as promising anticancer therapeutics. Curr Cancer Drug Targets 2008; 8: 299-340.
59. Howard OM, Ben-Baruch A, Oppenheim JJ. Chemokines: progress toward identifying molecular targets for therapeutic agents. Trends Biotechnol 1996; 14: 46-51.
60. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250: 91-104.
61. Greenman C, Stephens P, Smith R, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007; 446: 153-158.
62. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767.
63. Baranska M, Lewandowski K, Gniot M, et al. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene. J Appl Genet 2008; 49: 201-203.
64. Gonzales AJ, Hook KE, Althaus IW, et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther 2008; 7(7): 1880-9.
65. Socinski MA. The current status and evolving role of sunitinib in non-small cell lung cancer. J Thorac Oncol 2008; 3: S119-123.
66. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452: 564-570.
67. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826.
68. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
69. Ring BZ, Seitz RS, Beck R, et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptorpositive breast cancer. J Clin Oncol 2006; 24: 3039-3047.
70. Badve, S., Nakshatri, H.: WO2008094964A2 (2008).
71. Hennessy, B.T.J., Mills, G.B., Coombes, K., Gonzalez-Anguelo, A., Carey, M.: WO2008019375A2 (2008).
72. Lee, A.S., Cote, R.: WO2008042508A1 (2008).
73. Abdoler E, Taylor H, Wendler D. The ethics of phase 0 oncology trials. Clin Cancer Res 2008; 14: 3692-3697.